

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus dated November 29, 2022 (the “**Prospectus**”) of 3D Medicines Inc. (the “**Company**”).

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”) or any state securities laws of the United States and may not be offered, sold, pledged or otherwise transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act. The Company has not intended and does not intend to make any public offer of securities in the United States. The Offer Shares are being offered and sold solely (1) to qualified institutional buyers (as defined in Rule 144A under the U.S. Securities Act) pursuant to Rule 144A or another available exemption from registration under the U.S. Securities Act and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.



3D Medicines Inc.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1244)

PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that the Over-allotment Option described in the Prospectus has been partially exercised by the Joint Representatives on behalf of the International Underwriters on Friday, January 6, 2023 in respect of an aggregate of 415,000 Shares, representing approximately 2.54% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, to facilitate the return to Dragon Prosper Holdings Limited all the 415,000 borrowed Shares under the Stock Borrowing Agreement which were used to cover the over-allocation under the International Offering.

The Over-allotment Shares will be allotted and issued by the Company at HK\$24.98 per Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015%), being the Offer Price per Offer Share under the Global Offering.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company further announces that the stabilization period in connection with the Global Offering ended on Friday, January 6, 2023, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. Further information in relation to the stabilization actions undertaken by China Securities (International) Corporate Finance Company Limited, the Stabilizing Manager, or any person acting for it, during the stabilization period, is set out in this announcement.

PUBLIC FLOAT

Immediately after the end of the stabilization period and the completion of the partial exercise of the Over-allotment Option, the Company will continue to comply with the public float requirements under Rules 8.08(1)(a) and 18A.07 of the Listing Rules.

PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that the Over-allotment Option described in the Prospectus has been partially exercised by the Joint Representatives on behalf of the International Underwriters on Friday, January 6, 2023 in respect of an aggregate of 415,000 Shares (the “**Over-allotment Shares**”), representing approximately 2.54% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, to facilitate the return to Dragon Prosper Holdings Limited all the 415,000 borrowed Shares under the Stock Borrowing Agreement which were used to cover the over-allocation under the International Offering.

The Over-allotment Shares will be allotted and issued by the Company at HK\$24.98 per Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015%), being the Offer Price per Offer Share under the Global Offering.

APPROVAL FOR LISTING

Approval for the listing of and permission to deal in the Over-allotment Shares has already been granted by the Listing Committee of the Stock Exchange. Listing of and dealings in the Over-allotment Shares are expected to commence on the Main Board of the Stock Exchange at 9:00 a.m. on Wednesday, January 11, 2023 (Hong Kong time).

SHAREHOLDING STRUCTURE OF THE COMPANY UPON COMPLETION OF THE PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION

The shareholding structure of the Company immediately before and immediately after completion of the partial exercise of the Over-allotment Option is as follows:

Shareholders	Immediately before completion of the partial exercise of the Over-allotment Option		Immediately after completion of the partial exercise of the Over-allotment Option	
	Number of issued Shares	Approximate % of the Company's issued share capital	Number of issued Shares	Approximate % of the Company's issued share capital
Connected persons				
Dragon Prosper Holdings Limited ⁽¹⁾	35,992,364	14.08%	35,992,364	14.06%
Immunal Medixin US Limited	19,143,360	7.49%	19,143,360	7.48%
Immunal Medixin Cino L. Limited	9,571,680	3.74%	9,571,680	3.74%
Immunal Medixin Cino Limited	9,623,000	3.76%	9,623,000	3.76%
Shanghai Zhenlu Enterprise Management Consulting Partnership (Limited Partnership)	13,817,381	5.40%	13,817,381	5.40%
Sub-total	<u>88,147,785</u>	<u>34.48%</u>	<u>88,147,785</u>	<u>34.43%</u>
Public Shareholders				
Cornerstone Investors ⁽²⁾	9,391,500	3.67%	9,391,500	3.67%
Other public Shareholders	<u>158,102,715</u>	<u>61.85%</u>	<u>158,517,715</u>	<u>61.91%</u>
Sub-total	<u>167,494,215</u>	<u>65.52%</u>	<u>167,909,215</u>	<u>65.57%</u>
Total	<u><u>255,642,000</u></u>	<u><u>100.00%</u></u>	<u><u>256,057,000</u></u>	<u><u>100.00%</u></u>

Notes:

- (1) Inclusive of the 415,000 Shares borrowed by China Securities (International) Corporate Finance Company Limited, the Stabilizing Manager, or any person acting for it, under the Stock Borrowing Agreement.
- (2) These refer to all the Cornerstone Investors as set out in the section headed "Cornerstone Investors" of the Prospectus. The shareholding of each of the Cornerstone Investors immediately before the allotment of the Over-allotment Shares have been set out in the Company's announcement of offer price and allotment results dated December 14, 2022. The Over-allotment Shares to be issued by the Company will not affect the number of Shares held by each of the Cornerstone Investors, but will have a dilutive effect on the shareholding of the Cornerstone Investors on a pro rata basis.
- (3) Any discrepancies in the table between the totals and sums of amounts listed therein are due to rounding.

USE OF PROCEEDS

The Company will receive additional net proceeds of approximately HK\$10.4 million (after deducting the estimated expenses payable by the Company in connection with the partial exercise of the Over-allotment Option) for the 415,000 Shares to be issued and allotted following the partial exercise of the Over-allotment Option. The additional net proceeds will be used by the Company for the purposes and in the proportions as set out in the section headed “Future Plans and Use of Proceeds” in the Prospectus.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

Pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), the Company announces that the stabilization period in connection with the Global Offering ended on Friday, January 6, 2023, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. The stabilizing actions undertaken by China Securities (International) Corporate Finance Company Limited, the Stabilizing Manager, or any person acting for it, during the stabilization period are set out below:

- (i) the over-allocation of an aggregate of 415,000 Shares under the International Offering, representing approximately 2.54% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option;
- (ii) the borrowing of an aggregate of 415,000 Shares from Dragon Prosper Holdings Limited pursuant to the Stock Borrowing Agreement to cover the over-allocation under the International Offering; and
- (iii) the partial exercise of the Over-allotment Option by the Joint Representatives on behalf of the International Underwriters on Friday, January 6, 2023 in respect of an aggregate of 415,000 Shares, representing approximately 2.54% of the total number of Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, at HK\$24.98 per Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015%), being the Offer Price per Offer Share under the Global Offering, to facilitate the return to Dragon Prosper Holdings Limited of all the 415,000 borrowed Shares under the Stock Borrowing Agreement which were used to cover the over-allocation under the International Offering.

There had been no purchase or sale of any Shares on the market for the purpose of price stabilization by the Stabilization Manager during the stabilization period.

The portion of the Over-allotment Option which has not been exercised by the Joint Representatives on behalf of the International Underwriters lapsed on Friday, January 6, 2023.

PUBLIC FLOAT

Immediately after the end of the stabilization period and the completion of the partial exercise of the Over-allotment Option, the Company will continue to comply with the public float requirements under Rules 8.08(1)(a) and 18A.07 of the Listing Rules.

By order of the Board
3D Medicines Inc.
Dr. Gong Zhaolong
Chairman of the Board and Executive Director

Hong Kong, January 9, 2023

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Pai, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.